Efficacy and Safety of Treating Stage 2 Systolic Hypertension With Olmesartan and Olmesartan/HCTZ: Results of an Open‐Label Titration Study

This study investigated an aggressive treatment program for stage 2 systolic hypertension (pretreatment systolic blood pressure [SBP] ≥160 mm Hg) using the angiotensin receptor blocker olmesartan medoxomil (OM) and hydrochlorothiazide (HCTZ). In this open‐label, 16‐week trial, 170 subjects received...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Hypertens (Greenwich)
Egile Nagusiak: Izzo, Joseph L., Neutel, Joel M., Silfani, Tonous, Dubiel, Robert, Walker, Findlay
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Le Jacq 2007
Gaiak:
Original Papers
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8109941/
https://ncbi.nlm.nih.gov/pubmed/17215657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1524-6175X.2007.5713.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak